EUVIMEDEUVIMED entdecken
Crossref

Epigallocatechin-3-gallate inhibit the protein arginine methyltransferase 5 and enhancer of Zeste homolog 2 in breast cancer both in vitro and in vivo

Kirankumar Nalla, Biji Chatterjee, Jagadeesha Poyya, Aishwarya Swain, Krishna Ghosh, Archana Pan, Chandrashekhar G Joshi, Bramanandam Manavathi, Santosh R Kanade

Archives of Biochemistry and Biophysics · 2025

DOI: 10.1016/j.abb.2024.110223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Biochemistry and Biophysics, 2025. Verfasst von Kirankumar Nalla und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plant Sciences, School of Life Sciences University of Hyderabad PO Central University Gachibowli, Hyderabad Telangana, 500046, India. Hauptthemen laut MEDLINE: Catechin, Protein-Arginine N-Methyltransferases, Enhancer of Zeste Homolog 2 Protein, Breast Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 61 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Histone methyltransferases are enzymes that selectively methylate lysine or arginine residues on both histone and non-histone proteins, categorized into lysine methyltransferases and arginine methyltransferases. Notably, EZH2 and PRMT5 are known for catalyzing trimethylation of H3 at K27 and symmetric dimethylation of H4 at R3, respectively. These methylation events are recognized as characteristic histone-repressive marks in cancer. The over expression of PRMT5 and EZH2 were reported in various cancers and recognized as a drug target. The study aims to explore the inhibitory potential of phytocompound, Epigallocatechin-3-gallate (EGCG), against PRMT5 and EZH2 in the breast cancer model. METHODS: Screening of an array of phytocompounds was conducted through a combination of in-silico and in-vitro assays. Interactions between EGCG and human PRMT5: MEP50 and EZH2 were evaluated using molecular docking. Binding efficiency was validated, by Surface Plasmon Resonance studies and inhibitory potential was accessed by in vitro methylation followed by western blots, ELISA, and cell-based assays. In-vivo efficacy of EGCG was carried on cell line derived mice xenograft model. RESULTS: EGCG demonstrated robust interactions with PRMT5:MEP50 complex and EZH2, particularly within the SAM binding site. Surface Plasmon Resonance analysis revealed strong binding affinity in nanomolar concentrations, particularly with PRMT5-MEP50 compared to EZH2. In-vitro assays confirmed EGCG's ability to inhibit PRMT5 and EZH2, leading to a decrease in their catalytic products, namely H4R3me2s and H3K27me3, respectively. EGCG treatment induced both autophagy and apoptosis invitro. In-vivo studies demonstrated significant reductions in tumor size and the proliferation marker ki67, accompanied by a decrease in histone repressive marks. CONCLUSION: The findings suggest that EGCG effectively inhibits PRMT5 and EZH2, underscoring its potential for combined therapeutic strategies in cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CatechinProtein-Arginine N-MethyltransferasesEnhancer of Zeste Homolog 2 ProteinBreast NeoplasmsMolecular Docking SimulationHumansFemaleAnimalsMiceCell Line, TumorMice, NudeXenograft Model Antitumor AssaysCell ProliferationEnzyme InhibitorsMCF-7 CellsAdaptor Proteins, Signal TransducingTranscription Factors

Stichwörter der Autor:innen

ApoptosisAutophagyBreast cancerEGCGEZH2H3K27me3H4R3me2sPRMT5

Substanzen

CatechinProtein-Arginine N-MethyltransferasesEnhancer of Zeste Homolog 2 ProteinEnzyme InhibitorsAdaptor Proteins, Signal Transducingepigallocatechin gallateEZH2 protein, humanPRMT5 protein, humanWDR77 protein, humanTranscription Factors

Autor:innen und Institutionen

  • Department of Plant Sciences, School of Life Sciences University of Hyderabad PO Central University Gachibowli, Hyderabad Telangana, 500046, India.
  • Department of Genomic Medicine, The University of Texas MD Anderson Cancer Centre, Houston, TX, USA.
  • SDM Research Institute for Biomedical Sciences, A Constituent Unit of Shri Dharmasthala, Manjunatheshwara University, Dharwad, 580009, Karnataka, India.
  • Department for Bioinformatics, Pondicherry University, Puducherry, 605014, India.
  • Department of Anaesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Centre, Houston, TX, USA.
  • Department of Studies in Biochemistry, Mangalore University PG Centre, Jnana Kaveri, Chikka Aluvara, Thorenoor Post Kushalnagar, Somawarpet TQ, Kodagu, 571232, India.

Zitieren

APA

Nalla, K., Chatterjee, B., Poyya, J., Swain, A., Ghosh, K., Pan, A., Joshi, C. G., Manavathi, B., & Kanade, S. R. (2025). Epigallocatechin-3-gallate inhibit the protein arginine methyltransferase 5 and enhancer of Zeste homolog 2 in breast cancer both in vitro and in vivo. Archives of Biochemistry and Biophysics. https://doi.org/10.1016/j.abb.2024.110223

Vancouver

Nalla K, Chatterjee B, Poyya J, Swain A, Ghosh K, Pan A, et al. Epigallocatechin-3-gallate inhibit the protein arginine methyltransferase 5 and enhancer of Zeste homolog 2 in breast cancer both in vitro and in vivo. Archives of Biochemistry and Biophysics. 2025. doi:10.1016/j.abb.2024.110223

BibTeX
@article{Nalla2025,
  author = {Nalla, Kirankumar and Chatterjee, Biji and Poyya, Jagadeesha and Swain, Aishwarya and Ghosh, Krishna and Pan, Archana and Joshi, Chandrashekhar G and Manavathi, Bramanandam and Kanade, Santosh R},
  title = {Epigallocatechin-3-gallate inhibit the protein arginine methyltransferase 5 and enhancer of Zeste homolog 2 in breast cancer both in vitro and in vivo},
  journal = {Archives of Biochemistry and Biophysics},
  year = {2025},
  doi = {10.1016/j.abb.2024.110223}
}
Kostenlos starten →